49 results about "Addictive behavior" patented technology

The present invention is a method for the treatment of eating disorders by nerve tissue stimulation and infusion techniques to one or more areas of the brain affecting hunger and satiety; palatability and aversion; hedonism; reward / addiction behavior; mood; anxiety; depression, taste and smell. The invention also comprises methods for the treatment of disorders of these individual behaviors and in particular, disorders of taste and / or smell.

The present invention is directed to methods of treating addictive behavior and sleep disorders by administering compounds represented by structural Formula (I)or pharmaceutically acceptable salt forms thereof, wherein R1, R5, R6a, R6b, R7, R8, R9, X, b, k, m, and n, and the dashed lines are described herein. The compounds used in the method of treatment of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including addictive behavior and sleep disorders.

An addiction simulator for use in an educational program, operable for (i) periodically requesting simulated addictive behavior, (ii) receiving a satisfaction signal from an assigned individual in response to a generated request, representing consumption of an amount of addictant in limited supply, and (iii) refusing acceptance of a satisfaction signal when the supply of addictant has been exhausted. The duration of the interval between requests can based upon a physiological characteristic of the assigned individual.

The present invention is directed to novel compounds represented by structural Formula (I):or a pharmaceutically acceptable salt thereof, wherein R1, R4a, R5, R6, R7, R8, R9,and m, are defined herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain central nervous system disorders. The compounds of this invention are serotonin receptor modulators, in particular 5HT2C receptor agonists and antagonists, and are useful in the control or prevention of central nervous system disorders including obesity, anorexia, bulemia, depression, anxiety, psychosis, schizophrenia, migraine, addictive behavior, obsessive-compulsive disorder, and sexual disorders.

A method of providing support for, and monitoring of, an individual recovering from addictive behaviors, mental health issues, or other chronic health concerns comprises a multi-tiered support system for the recovering individual and monitoring the recovering individual's commitment to recovery. The basic set of activities that may be integrated into a program include: (1) periodic review sessions with a program monitor; (2) attendance at Twelve-Step meetings; (3) daily online activity reporting; (4) online educational assignments; (5) community service commitments; (6) a recreational activity undertaken by the individual; and, (7) drug and / or biological fluid testing where applicable. The daily online activity reporting feature allows for support to be provided for a person seeking support services. If the person fails to engage in the daily activity reporting, an alert notification can be triggered to allow doctors, treatment providers, friends, and / or family to provide needed support for, and increase the accountability of, the person receiving support services.

The present invention is directed to compounds useful for treating addictive behavior and sleep disorders represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R1, R5, R6a, R6b, R7, R8, R9, X, b, k, m, and n, and the dashed lines are described herein. The compounds used in the method of treatment of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including addictive behavior and sleep disorders.

This invention provides a method of mitigating / ameliorating one or more components of addictive behavior associated with chronic consumption of a substance of abuse, or withdrawal therefrom. The method typically involves administering to a subject in need thereof an adenosine A2A receptor antagonist in an amount sufficient to ameliorate said one or more components of addictive behavior.

The gene (SLC6A4) responsible for encoding the serotonin transporter (SERT) has a functional polymorphism at the 5′-regulatory promoter region, which results in two forms, long (L) and short (S). The LL-genotype is hypothesized to play a key role in the early onset of alcohol use. The present invention discloses the differences in treatment and diagnosis based on the L or short genotypes as well as on a single nucleotide polymorphism of the SERT gene, the 3′ UTR SNP rs1042173. The present invention demonstrates the efficacy of using the drug ondansetron and similar drugs for treatment based on diagnosing variations in the polymorphisms of the SERT gene and expression and activity of the SERT gene, as well as methods for diagnosing susceptibility to abuse of alcohol and other addiction-related diseases and disorders, for monitoring treatment and / or abuse (addictive behavior), and for determining which treatment should be used.

The present invention relates to methods of treating or preventing addiction and relapse use of addictive agents and treating or preventing addictive or compulsive behavior and relapse practice of an addictive behavior or compulsion. The methods and compositions of the invention are useful in the treatment or prevention of addiction to any agent, including alcohol, nicotine, marijuana, cocaine, and amphetamines, as well as compulsive and addictive behaviors, including pathological gambling and pathological overeating.

Formulations have been developed which assist individuals having an addiction such as smoking to reduce or quit engaging in the addictive behavior. Representative behaviors include smoking, excessive alcohol or food ingestion, drug addiction, and ingestion of caffeine or junk food providing quick “highs”. The formulations assist the smoker to become dissatisfied with smoking, until he or she willingly gives up the habit or at least cuts down on the number of cigarettes smoked per day as an initial step towards quitting in the future. The formulations can also be used in conjunction with other known formulations, such as nicotine gum or patch. The formulations contain hydrophilic polymers, for example, polyethylene glycol (PEG) alone or in combination or polyvinyl pyrrolidone (PVP) (also known as povidone or polyvidone alone or in combination.), sweeteners and / or flavorings, viscosity modifiers / binders, and pH or buffering agents.

Improved compositions and methods are useful in the treatment and prevention of impulsive, compulsive, reward-seeking, and other addictive behaviors, including applications involving the behavioral / cognitive process of assigning importance, maintaining attention, and assessing salience. The composition includes Vitex agnus-castus (Chastetree berry) extract in an effective amount for supporting and promoting a healthy lifestyle free from addictive behavior or for preventing or treating addictive behavior. The composition also includes garcinia cambogia, aspartic acid, pyruvate, EPA (eicosapentanoic acid), biotin, L-carnitine, and chromium polynicotinate.

Methods and compositions are disclosed to treat neuropsychiatric disorders based upon a new framework of diagnosis. Axis I biomarkers include genes related to prefrontal dopamine synthesis and / or dopamine degradation. Axis II includes genes related to re uptake of dopamine, norepinephrine and serotonin and autonomic hyperactivity. Axis III includes genes relates to impairments in inflammatory pathways, glutamate neurotransmission and / or neurotrophic factors. Axis IV includes genes related to glutamate reuptake and predisposition to addictive behavior, and obsessive compulsions.

Disclosed is a new antibody which can be used to relieve addiction caused by nerve active substances, including opium, cocaine, benzedrine, ketamine, etc. Cocain and amphetamine-regulated transcript peptide antibody gene is selected through phage display technology; then single-chain antibody sequence of the cocain and amphetamine-regulated transcript peptide(CART) and the procaryon expression vector are connected and are induced to express and to be purified to obtain single-chain antibody in response to CART, which is named as CARTscFv(AH1,AH4B,AH6,AH19,AH33B,AH36). Injecteion of CARTscFv into the abdominal cavity of a mouse, together with the CART at the peripheral circulation system, leads to the reduction of the CART in the central nervous system of the mouse. Animal model with behavioral sensitization induced by cocain proves that the CART single-chain antibody can restrain the expression of the behavioral sensitization of the mouse induced by cacain, which shows that the CART single-chain antibody is of great potential in curing addiction and particularly relapse caused by nerve active.

A system for treating addictions includes genetic testing to determine the presence of allelic variants of genes shown to be associated with impulsive / addictive behaviors and a tailored rehabilitation regimen of specific physical exercise, special diet and particular dietary supplements to optimize the way mood elevation is achieved in the patient. The system further includes individual and group counseling and initial oxygen therapy. The genetic testing assesses the presence of gene polymorphism in at least one of D2 dopamine receptor gene (DRD2), dopamine transporter gene (DAT1), dopamine beta-hydroxylase gene (DBH) and serotonin transporter (SERT) gene. The dietary supplements are tailored to stimulate production of neuromediators or neurotransmitters, depending upon the polymorphism determined. The exercises include static and dynamic routines also tailored to the results of the genetic testing. After completion of the inpatient portion of the system, further therapies include daily exercise and dietary supplement programs tailored for each polymorphism discovered.

The invention discloses a zebrafish pain sense memory and addiction behavior experiment device and method. According to the invention, a clamping plate is arranged on the wall of a fish tank; an automatic elastic shrinkage device is arranged at the upper end of the clamping plate and connected with a food-intake behavior-pain sense memory module used for training zebrafish to form food-intake behavior-pain sense memory through a titanium alloy wire; the food-intake behavior-pain sense memory module is connected with an addiction behavior module arranged on the clamping plate; the addiction behavior module is used for evaluating zebrafish addiction related behaviors; a video acquisition unit and an LED lamp panel capable of performing four-color switching are arranged below the clamping plate; the video acquisition unit is used for acquiring zebrafish behavior tracks of an experimental area; and related behavioral changes and motion track analysis are performed through a control computer. According to the invention, the problem of the disadvantages of a conventional advanced cognitive function evaluation method for long-term / short-term memory, work memory, thinking conversion ability, addiction-related behaviors and the like in the zebrafish research process is solved; and a powerful software and hardware support is provided for research in related fields.

The present invention relates to methods of treating or preventing addiction and relapse use of addictive agents, and treating or preventing addictive or compulsive behaviour and relapse practice of an addictive behaviour or compulsion, by administering a peroxisome proliferator-activated receptor gamma (PPARγ) agonist, alone or in combination with another therapeutic agent, such as, for example, an opioid receptor antagonist or an antidepressant, or an addictive agent, such as, for example, an opioid agonist. The present invention also includes pharmaceutical compositions for treating or preventing addiction or relapse that include a PPARγ agonist and one or more other therapeutic or addictive agents, as well as unit dosage forms of such pharmaceutical compositions, which contain a dosage effective in treating or preventing addiction or relapse. The methods and compositions of the invention are useful in the treatment or prevention of addiction to any agent, including alcohol, nicotine, marijuana, cocaine, and amphetamines, as well as compulsive and addictive behaviours, including pathological gambling and pathological overeating.

The invention is directed at the formulation of Mucuna pruiens, N Acetyl L Cysteine and Magnesium Citrate. This formulation augments dopamine in the striatal area of the human brain and stabilizes membranes by restoring normal neurotransmitter levels and decreasing endogenous catecholamines. These effects are beneficial in the short and long term treatment of addictive disease and addiction to chemical substances and addictive behaviors.

The present invention is directed to a method of treating or preventing an addictive behavior in a subject, said method comprising administering to said subject an effective amount of a dopamine antagonist and a opiate receptor antagonist or a composition comprising same. Further provided are pharmaceutical compositions comprising, as active substances, at least one dopamine antagonist and at least one opiate receptor antagonist.

The present invention relates to methods of treating or preventing addiction and relapse use of addictive agents where the method comprises: (a) administering to a subject a co-therapy treatment with an auricular or peri-auricular electro-acupuncture or neurostimulation device, (b) co-treatment with at least one non-narcotic detoxification agent and (c) administering to the subject an opioid antagonist. The methods and compositions of the invention are useful in the treatment or prevention of addiction to any agent, including alcohol, nicotine, marijuana, cocaine, and amphetamines, as well as compulsive and addictive behaviors, including pathological gambling and pathological overeating.

The present invention provides a method for treating addictive behavior, comprising administering Dextromethorphan (DM) to a subject suffering addictive behavior. The present invention also provides a method for treating bipolar disorder, comprising administering Dextromethorphan (DM) to a subject suffering bipolar disorder.

The present invention provides compounds of formula I: a stereoisomer or a pharmaceutically acceptable salt thereof, wherein the variables R1, R2, R3, R4, X and n are defined as defined herein. Additionally, a method for treating dopamine-related neurological disorders selected form the group consisting of neurological, psychological, cardiovascular, cognitive or attention disorders, substance abuse and addictive behavior, or a combination thereof, comprising administering to a patient in need of such treatment a therapeutically effective amount of compounds of formula I.

The invention relates to the treatment of impulsivity-related disorders, such as a substance-related addiction, a behavioural addiction, relapse to a substance-related or behavioural addiction, a habit or impulsive disorder, an emotional unstable personality disorder, intentional self harm, an eating disorder, a dopamine agonist-induced impulse control disorder, or attention deficit hyperactivity disorder (ADHD) by administering a compound of Formula I or a salt thereof to a subject; Formula (I) wherein: E is S or Se; R1 and R2 are optional substituents, and are at each occurrence independently selected from: (1) a halogen, which is preferably selected from F, CI and Br; (2) C1-C4 alkyl, such as C1-C2 alkyl or C1 alkyl, optionally substituted with one or more halogen atoms, each of which is preferably selected from F, CI and Br; and (3) C1-C4 alkoxy, such as C1-C2 alkoxy or C1 alkoxy; optionally substituted with one or more halogen atoms, each of which is preferably selected from F, CI and Br; m is an integer in the range of from 0 to 5; and n is an integer in the range of from 0 to 4. The compound can also be used to treat or control impulsivity control disorders in patients undergoing dopamine agonist treatment, for example in patients suffering from Parkinson's disease or ADFID.